` 2616 (CStone Pharmaceuticals) vs Hang Seng (Hong Kong) Comparison - Alpha Spread

2616
vs
H
Hang Seng (Hong Kong)

Over the past 12 months, CStone Pharmaceuticals has significantly outperformed Hang Seng (Hong Kong), delivering a return of +133% compared to the Hang Seng (Hong Kong)'s +30% growth.

Stocks Performance
2616 vs Hang Seng (Hong Kong)

Loading
2616
Hang Seng (Hong Kong)
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
2616 vs Hang Seng (Hong Kong)

Performance Gap Between 2616 and HSI
HIDDEN
Show

Performance By Year
2616 vs Hang Seng (Hong Kong)

Loading
2616
Hang Seng (Hong Kong)
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
CStone Pharmaceuticals vs Peers

Hang Seng (Hong Kong)
2616
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

CStone Pharmaceuticals
Glance View

Market Cap
8.4B HKD
Industry
Biotechnology

Cstone Pharmaceuticals Co. Ltd. engages in the research and development of highly complex biopharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 264 full-time employees. The company went IPO on 2019-02-26. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The firm conducts its businesses mainly in domestic market.

CStone Pharmaceuticals Intrinsic Value
HIDDEN
Show
Back to Top